Search results for "SR141716A"

showing 1 items of 1 documents

Long-term effects on cortical glutamate release induced by prenatal exposure to the cannabinoid receptor agonist (r)-(+)-[2,3-dihydro-5-methyl-3-(4-m…

2003

The aim of the present in vivo microdialysis study was to investigate whether prenatal exposure to the CB1 receptor agonist WIN55,212-2 mesylate (WIN; (R)-()-(2,3- dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo(1,2,3-de)- 1,4-benzoxazin-6-yl)-1-naphthalenylmethanone), at a dose of 0.5 mg/kg (s.c. from the fifth to the 20th day of gestation), that causes neither malformations nor overt signs of toxicity, influences cortical glutamate extracellular levels in adult (90- day old) rats. Dam weight gain, pregnancy length and litter size at birth were not significantly affected by prenatal treatment with WIN. Basal and K-evoked dialysate glutamate levels were lower in the cerebral cortex of adul…

MaleAgonistmedicine.medical_specialtyMicrodialysisTime FactorsCannabinoid receptormedicine.drug_classMicrodialysisMorpholinesGlutamic Acidmaternal marijuana consumptionNaphthalenesBiologyTimechemistry.chemical_compoundGlutamatergicPiperidinesPregnancyInternal medicinebasal and K -evoked glutamate levelsmedicineAnimalsDrug InteractionsWakefulnessNeurotransmitterReceptorSR141716A; basal and K+-evoked glutamate levels; maternal marijuana consumptionCerebral CortexAnalysis of VarianceDose-Response Relationship DrugCannabinoidsGeneral NeuroscienceGlutamate receptorBenzoxazinesRatsEndocrinologyAnimals NewbornchemistryPrenatal Exposure Delayed EffectsSR141716AToxicityPotassiumPyrazolesSR141716A; basal and K -evoked glutamate levels; maternal marijuana consumption.CalciumFemaleRimonabantExtracellular Space
researchProduct